Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytoreductive surgery in patients with recurrent or metastatic gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of two Russian cancer centers.
Filonenko D, Arkhiri P, Nikulin M, Sagaidak I, Yugai V, Zhukova L, Meshcheryakov A. Filonenko D, et al. Among authors: meshcheryakov a. Transl Gastroenterol Hepatol. 2023 Nov 28;9:7. doi: 10.21037/tgh-23-38. eCollection 2024. Transl Gastroenterol Hepatol. 2023. PMID: 38317747 Free PMC article.
Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.
Shebzukhov YV, Koroleva EP, Khlgatian SV, Belousov PV, Kuz'mina KE, Radko BV, Longpre F, Lagarkova MA, Kadachigova TS, Gurova OV, Meshcheryakov AA, Lichinitser MR, Knuth A, Jager E, Kuprash DV, Nedospasov SA. Shebzukhov YV, et al. Among authors: meshcheryakov aa. Int J Cancer. 2005 Dec 10;117(5):800-6. doi: 10.1002/ijc.21240. Int J Cancer. 2005. PMID: 15981215 Free article.
[Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV, Zavalishina LE, Ganshina IP, Andreeva YY, Frank GA, Gordeeva OO, Zhukova LG, Meshcheryakov AA, Savelov NA, Tuzova EA, Morozov DA, Poddubnaya IV. Kolyadina IV, et al. Among authors: meshcheryakov aa. Arkh Patol. 2019;81(6):56-62. doi: 10.17116/patol20198106156. Arkh Patol. 2019. PMID: 31851193 Russian.
Surgical and combined treatment of patients with duodenal stromal tumors.
Arkhiri PP, Stilidi IS, Nered SN, Abgaryan MG, Nikulin MP, Meshcheryakov AA, Filonenko DA, Egenov OA, Yugai VV, Volkov AY. Arkhiri PP, et al. Among authors: meshcheryakov aa. Khirurgiia (Mosk). 2021;(8):11-19. doi: 10.17116/hirurgia202108111. Khirurgiia (Mosk). 2021. PMID: 34363440 English, Russian.
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Eggermont AM, Meshcheryakov A, Atkinson V, Blank CU, Mandala M, Long GV, Barrow C, Di Giacomo AM, Fisher R, Sandhu S, Kudchadkar R, Ortiz Romero PL, Svane IM, Larkin J, Puig S, Hersey P, Quaglino P, Queirolo P, Stroyakovskiy D, Bastholt L, Mohr P, Hernberg M, Chiarion-Sileni V, Strother M, Hauschild A, Yamazaki N, van Akkooi AC, Lorigan P, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C. Eggermont AM, et al. Among authors: meshcheryakov a. Eur J Cancer. 2021 Oct 18;158:156-168. doi: 10.1016/j.ejca.2021.09.023. Online ahead of print. Eur J Cancer. 2021. PMID: 34678677 Free article.
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suciu S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Kennedy OJ, et al. Among authors: meshcheryakov a. Eur J Cancer. 2023 Aug;189:112900. doi: 10.1016/j.ejca.2023.04.016. Epub 2023 Apr 29. Eur J Cancer. 2023. PMID: 37277264 Clinical Trial.
29 results